EmTheraPro
Decatur, US · Founded 2021 · Georgia corporation
Emtherapro develops biomarkers and therapies for neurodegenerative diseases, including Alzheimer's disease, using proteomics-based methods. It partners with researchers, biotech and pharmaceutical companies, and healthcare organizations to create new diagnostics and therapies.
Founders & leadership
KP
Kiran PandeyCEO
AL
Allan LeveyNamed on SEC filing
NS
Nicholas SeyfriedNamed on SEC filing
DD
Duc DuongNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$3M disclosed across 1 round · 2023
▶$3MraisedSep 2023 · 1 investors · Other Health CareRule 506(b)
▶$3MraisedSep 2023 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Allan LeveyExecutive Officer, Director
- Nicholas SeyfriedExecutive Officer, Director
- Kiran Kumar PandeyExecutive Officer
- Duc DuongExecutive Officer, Director
- Offering amount
- $3M
- Amount sold
- $3M
- First sale
- Aug 2023
- Incorporated
- Corporation, Georgia, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does EmTheraPro do?
- Emtherapro develops biomarkers and therapies for neurodegenerative diseases, including Alzheimer's disease, using proteomics-based methods. It partners with researchers, biotech and pharmaceutical companies, and healthcare organizations to create new diagnostics and therapies.
- How much funding has EmTheraPro raised?
- EmTheraPro has disclosed $3M raised across 1 round.
- Where is EmTheraPro headquartered?
- EmTheraPro is headquartered in Decatur, US.